

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES
PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001468223
Filer CCC XXXXXXXXX
Is this a LIVE or TEST Filing? LIVE TEST

Submission Contact Information

Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer Tango Therapeutics, Inc.
SEC File Number 001-39485
Address of Issuer 201 Brookline Ave
Suite 901
Boston
MASSACHUSETTS
02215
Phone 857-320-4900

Name of Person for Whose Account the Securities are To Be Sold MVA Investors, LLC

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer member of group owning over 10% of the shares

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	BofA Securities Inc. 1111 Ave of the Americas One Bryant Park New York NY 10036-6706	75000	577500	106718315	05/01/2024	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the	Date you	Nature of	Name of Person	Is	Date	Amount of	Date of	Nature of
--------------	----------	-----------	----------------	----	------	-----------	---------	-----------

Class	Acquired	Acquisition Transaction	from Whom Acquired	this a Donor Acquired Gift?	Securities Acquired	Payment	Payment *
Common Stock	04/07/2020	Private Financing	Tango Therapeutics, Inc.	<input type="checkbox"/>	21082	04/07/2020	Cash
Common Stock	03/11/2021	Private Financing	Tango Therapeutics, Inc.	<input type="checkbox"/>	30442	03/11/2021	Cash
Common Stock	10/12/2022	Open Market Purchases	Tango Therapeutics, Inc.	<input type="checkbox"/>	23476	10/12/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks Aggregate Market Value as of 4/30/2024.
Date of Notice 05/01/2024
ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Aaron Davis, Chief Executive Officer

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)